Chiba Jun, Muro Fumihito, Setoguchi Masaki, Machinaga Nobuo
Lead Discovery & Optimization Research Laboratories II, Daiichi Sankyo Co. Ltd., 1–2–58 Hiromachi, Shinagawaku, Tokyo, Japan.
Chem Pharm Bull (Tokyo). 2012;60(7):882-6. doi: 10.1248/cpb.c12-00023.
This contribution describes a concise synthesis to ethyl trans-[(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate (2b) as a key intermediate of very late antigen-4 (VLA-4) antagonist trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxyamide)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid (1). The synthesis employs a reductive etherification as a key reaction using (2S,4S)-1-benzyloxycarbonyl-4-methoxypyrrolidine-2-carboxyaldehyde (12) and trans-4-triethylsilyloxycyclohexanecarboxilic acid ethyl ester (13b). This synthesis provides 2b in 6 steps with 38% overall yield from commercially available starting material.
本论文介绍了一种简洁的合成方法,用于制备反式-[(4S)-甲氧基-(2S)-吡咯烷甲基氧基]环己烷羧酸乙酯(2b),它是极晚期抗原-4(VLA-4)拮抗剂反式-4-[1-[[2,5-二氯-4-(1-甲基-3-吲哚基甲酰胺基)苯基]乙酰基]-(4S)-甲氧基-(2S)-吡咯烷甲基氧基]环己烷羧酸(1)的关键中间体。该合成方法采用还原醚化反应作为关键反应,使用(2S,4S)-1-苄氧羰基-4-甲氧基吡咯烷-2-甲醛(12)和反式-4-三乙基硅氧基环己烷羧酸乙酯(13b)。该合成方法从市售原料出发,经6步反应得到2b,总收率为38%。